AstraZeneca has sponsored the development of the Diagnostic Mutation Database (DMuDB) into a National UK Database of variants in the EGFR gene associated with non-small cell lung cancer (NSCLC) tumours. The database will provide clinical, treatment and outcome data for patients  and offers support to laboratories for the interpretation of variants found in the EGFR gene. This testing is used to indicate sensitivity to EGFR-TKIs (e.g. IRESSA).

The year long sponsorship will allow NGRL to modify DMuDB, collect existing EGFR data from UK laboratories and engage an expert curator to collect future data.